NeoMatrix Therapeutics is a clinical-stage company dedicated to developing novel, bioactive peptides that prevent injury progression and thereby rescue tissue and speed healing. Our lead candidates focus on the treatment of severe burns and have the potential to significantly improve the quality of life and clinical outcomes of burn patients by limiting injury progression following the initial burn. This shortens healing time and reduces scarring. Continuing tissue destruction following an initial injury is a problematic phenomenon that occurs in many types of conditions, giving our novel peptides the potential to be used in multiple settings other than burns.